Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 46, Issue SUPPL., 2003, Pages 33-39

  Motzer, Robert J ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Memorial Hospital   (United States)

Author keywords

Clinical trials; Prognostic factors; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; RETINOID;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; HUMAN; KIDNEY CARCINOMA; MEDICAL LITERATURE; METASTASIS; PROGNOSIS; RISK;

EID: 0038354576     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00062-3     Document Type: Conference Paper

References (50)

1. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163:2000;408-417.
2. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 353:1999;14-17.
3. Pyrhonen S., Salminen E., Lehtonen T., et al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma. A phase III study. Proc. Am. Soc. Clin. Oncol. 15:1996;244Z. Abstract.
4. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. New Engl. J. Med. 345:2001;1655-1659.
5. Fyfe G., Fisher S.A., Sznol M., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:1995;688-696.
6. Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6:2002;S55-S57.
7. Sleijfer D.T., Janssen R.A., Buter J., et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 10:1992;1119-1123.
8. Krown S.E. Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer. 59:1987;647-651.
9. Neidhart J.A., Anderson S.A., Harris J.E., et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J. Clin. Oncol. 9:1991;832-836.
10. Minasian L.M., Motzer R.J., Gluck L., et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11:1993;1368-1375.
11. Fossa S.D., Martinelli G., Otto U., et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann. Oncol. 3:1992;301-305.
12. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48:1988;7310-7313.
13. De Forges A., Rey A., Klink M., et al. Prognostic factors of adult metastatic renal cell carcinoma: a multivariate analysis. Sem. Surg. Oncol. 4:1988;149-154.
14. Palmer P.A., Vinke J., Philip T., et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3:1992;475-480.
15. Jones M., Selby P., Franks C., et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biotherap. 8:1993;275-288.
16. Fossa S.D., Kramer A., Droz J.P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer. 30A:1994;1310-1314.
17. Hanninen E.J., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive patients. J. Urol. 155:1996;19-25.
18. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17:1999;2530-2540.
19. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 13:2002;1460-1468.
20. Zisman A., Pantuck A.J., Wieder J., Chao D.H., Dorey F., Said J.W., deKernion J.B., Figlin R.A., Belldegrun A.S. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21:2002;185a. abstract 737.
21. Flanigan R.C., Blumenstein B.A., Salmon S., et al. Cytoreduction nephrectomy in metastatic renal cancer: the results of the Southwest Oncology Group trial 8949. Proc. Am. Soc. Clin. Oncol. 19:2000;2a. abstract 3.
22. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20:2002;289-296.
23. Stadler W.M., Kuzel T., Dumas M., et al. A multi-center phase II trial of interleukin-2, interferon-alpha, and 13 cis-retinoic acid in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 16:1998;1820-1825.
24. Motzer RJ, Mazumdar M, Bacik J, et al., Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma, J Clin Oncol 99 A.D.;18:1928-35.
25. Rini B., Vogelzang N., Dumas M., et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J. Clin. Oncol. 18:2000;2419-2426.
26. Ryan C.W., Vogelzang N.J., Stadler W.M. A phase II trial of intravenous gemcitabine and 5-flourouracil with subcutaneous interleukin-2 and interferon-alfa in patients with metastatic renal cell carcinoma. Ann. Oncol. 94:2002;2602-2609.
27. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of interferon alfa-2a versus interferon alfa-2a plus 13-cis-retinoic acid in patients with advanced renal cell carcinoma. J. Clin. Oncol. 18:2000;2972-2980.
28. Motzer R.J., Rakhit A., Ginsberg M., et al. Phase I trial of 40 kDA branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J. Clin. Oncol. 19:2001;1312-1319.
29. Motzer R.J., Rakhit A., Schwartz L.H., et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4:1998;1183-1191.
30. Atkins M.B., Robertson M.J., Gordon M., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3:1997;409-417.
31. Berg W.J., Bukowsk R., Thompson J., et al. A randomized phase II trial of recombinant human interleukin-12 (IL-12) versus interferon alpha-2a (IFN) in advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 17:1998;318a. abstract.
32. Wigginton J.M., Komschlies K.L., Back T.C., et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88:(1):1996;38-43.
33. Yang J.C., Topalian S.L., Parkinson D., et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the thrapy of metastatic rnel cell carcinoma: an interim report. J. Clin. Oncol. 12:1994;1572-1576.
34. Yang J.C., Rosenberg S.A. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Am. 3:1997;S79-S84.
35. Atkins M.B., Dutcher J.P. Renal-cell carcinoma. New Engl. J. Med. 336:1997;809. letter.
36. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. New Engl. J. Med. 343:2002;750-758.
37. Rini B., Zimmerman T., Stadler W., Gajewski T.F., Vogelzang N.J. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. 20:2002;2017-2024.
38. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. New Engl. J. Med. 335:1996;865-875.
39. Linehan W.M. Renal cell carcinoma. Vogelstein B., Kinzler K. The genetic basis of human cancer. 1998;455-473 McGraw-Hill, New York.
40. Campbell S.C. Advances in angiogenesis research: relevance to urological oncology. J. Urol. 158:2001;1663-1674.
41. Eisen T., Boshoff C., Sapunar F., et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer. 82:1999;812-817.
42. Minor D., Elias A. Thalidomide treatment of metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 19:2000;352a.
43. Li Z., Amato R., Papandreou C., et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma progressing after interleukin-2 based therapy. Proc. Am. Soc. Clin. Oncol. 20:2001;180a.
44. Cho M.D., Konishi N., Kitahori Y., et al. Detection of DNA amplification in human renal cell carcinoma cell lines using restriction landmark genomic scanning. Cell Mol. Biol. 44:1998;913-918.
45. Amato R.J., Breheny S., Tracy E. Phase I/II study of thalidomide plus interleukin-2 for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21:2002;190a. abstract 759.
46. Hideschima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human mulitple myeloma cells to conventional therapy. Blood. 96:2000;2943-2950.
47. Yang J.C., Haworth L., Steinberg S.M., Rosenberg S.A., Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;5a. abstract 15.
48. Motzer RJ, Amato R, Todd M, Hwu W, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Needle M. Phase II trial of antiepidermal growth factor receptor antibody C225 in patient with advanced renal cell carcinoma, Invest New Drugs 2002, in press.
49. Drucker B.J., Schwartz L., Marion S., Motzer R. Phase II trial of ZD (Iressa), an EGF inhibitor, in patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21:2002;181a. abstract 720.
50. Atkins M.B., Hidalgo M., Stadler W., Logan T., Dutcher J.P., Hudes G., Park Y., Marshall B., Boni J., Dukart G. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21:2002;10a. abstract 36.